NASDAQ:KITE

(KITE) - KITE Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.

Add

Today's Range: $179.79
▼
$179.79
50-Day Range: N/A
52-Week Range: $39.82
▼
$179.99

Volume: N/A
Average Volume: 1.65 million shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Profile

Financials

Insider Trades

Institutional Ownership

Headlines

Options Chain

Social Media

About (KITE) (NASDAQ:KITE) Stock

Kite Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to target and kill cancer cells. The Company offers engineered autologous cell therapy, which is an approach to the treatment of cancer. Its therapy involves modifying a patient's T cells outside the patient's body, or ex vivo, causing the T cells to express chimeric antigen receptors (CARs), or T cell receptors (TCRs), and then reinfusing the engineered T cells back into the patient. Its lead product candidate, KTE-C19, is a CAR-based therapy that targets the CD19 antigen, a protein expressed on the cell surface of B-cell lymphomas and leukemias. The Company is conducting a registrational Phase II clinical trial (ZUMA-1) of KTE-C19 in patients with relapsed or refractory aggressive diffuse large B cell lymphoma (DLBCL), primary mediastinal B cell lymphoma (PMBCL), or transformed follicular lymphoma (TFL).

Receive KITE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (KITE) and its competitors with MarketBeat's FREE daily newsletter.

KITE Stock News Headlines

February 15, 2023 | msn.com

Extra parking bays for kite fest visitors

February 9, 2023 | msn.com

2023 Beloved Blossom Kite Festival to be held on Saturday, March 25

March 25, 2023 | Investor Place Media (Ad)

The "King Of Quants" sees 10X potential...

Eric Fry believes he just discovered America's next "Wealth Supercluster" and it's forming in the place you'd least expect. Investors are already flocking there for a chance at 1,000%+ returns. Here's how you could join them before it's too late...

February 9, 2023 | markets.businessinsider.com

Kite's Tecartus CAR T-Cell Therapy Shows Sustained Benefit In 3-year Follow-up Of ZUMA-3 Trial

February 9, 2023 | msn.com

Watch: Tree trimming service rescues seagull caught in kite string

October 26, 2022 | msn.com

Omri Katz was high as a kite filming Hocus Pocus

October 26, 2022 | msn.com

From beating drums to kite-flying, the bizarre British colonial-era laws India wants to scrap

October 26, 2022 | it.tmcnet.com

Black Kite Wins Two 2022 CISO Choice Awards for its Leading Cyber Risk Monitoring Platform

March 25, 2023 | Weiss Ratings (Ad)

Urgent Warning

This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …

October 26, 2022 | finance.yahoo.com

Kite, a Gilead Company Named Presenting Sponsor of Celebration & Community for The Leukemia & Lymphoma Society's National Light The Night Events

October 14, 2022 | seekingalpha.com

Kite Realty Stock: Market Is Overlooking Its Potential (NYSE:KRG) - Seeking Alpha

October 14, 2022 | cnn.com

'All That Breathes': Delhi's bird saviors become the subject of a hit documentary - CNN

October 7, 2022 | finance.yahoo.com

Kite Realty Group Trust to Report Third Quarter 2022 Financial Results on November 2, 2022 - Yahoo Finance

October 6, 2022 | globenewswire.com

Kite Realty Group Trust to Report Third Quarter 2022 Financial Results on November 2, 2022 - GlobeNewswire

October 4, 2022 | nasdaq.com

Ex-Dividend Reminder: Lincoln National, Globe Life and Kite Realty Group Trust - Nasdaq

September 29, 2022 | businesswire.com

Kite Lake Capital Management (UK) LLP UK Regulatory Announcement: Form 8.3 - Biffa plc - Business Wire

September 28, 2022 | msn.com

'High as a kite' man barged into family's Hartshill home and trashed the place

September 28, 2022 | finance.yahoo.com

KOCCA Hosts the 3rd KITE: K-POP in the Emirates in Dubai

September 28, 2022 | msn.com

BR experiencing good kite flying weather

September 28, 2022 | msn.com

Dragon, whale and octopus kites soar at international kite festival

September 28, 2022 | businesswire.com

KOCCA Hosts the 3rd KITE: K-POP in the Emirates in Dubai - Business Wire

September 27, 2022 | msn.com

Dragon, whale and octopus kites soar at international kite festival - msnNOW

September 26, 2022 | nasdaq.com

Kite Realty Group Trust is Oversold - Nasdaq

September 26, 2022 | msn.com

Zerodha rubbishes rumours about app being down, says Kite web login process changed

September 23, 2022 | msn.com

Long Beach Kite Festival To Celebrate Hispanic Heritage Month - msnNOW

September 19, 2022 | benzinga.com

Where Kite Realty Gr Trust Stands With Analysts - Kite Realty Gr Trust (NYSE:KRG) - Benzinga

September 17, 2022 | nasdaq.com

Gilead: Kite's CAR T-cell Therapy Yescarta Gets Positive Opinion From CHMP In EU - Nasdaq

See More Headlines

Receive KITE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (KITE) and its competitors with MarketBeat's FREE daily newsletter.

KITE Company Calendar

Last Earnings: 2/28/2017
Today: 3/25/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: N/A
Sub-Industry: N/A
Sector: N/A
Current Symbol: NASDAQ:KITE
CUSIP: N/A
CIK: 1510580
Web: www.kitepharma.com
Phone: +1-310-8249999
Fax: N/A
Employees: N/A
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Optionable
Beta: N/A

Key Executives

Arie S. Belldegrun
Executive Chairman of the Board, President, Chief Executive Officer, Founder

Paul L. Jenkinson
Chief Financial Officer

Cynthia M. Butitta
Chief Operating Officer

David Chang M.D. Ph.D.
Executive Vice President - Research and Development, Chief Medical Officer

Helen S. Kim
Executive Vice President - Business Development

Timothy L. Moore
Executive Vice President - Technical Operations

Christine Cassiano
Senior Vice President - Corporate Communications and Investor Relations

Bio & Compensation -

Jian Irish Ph.D.
Senior Vice President - Supply Chain

Bio & Compensation -

Jeffrey Wiezorek M.D.
Senior Vice President - Clinical Development

Shawn Cline Tomasello
Chief Commercial Officer

KITE Stock - Frequently Asked Questions

How were (KITE)'s earnings last quarter?: (KITE) (NASDAQ:KITE) released its quarterly earnings results on Tuesday, February, 28th. The biopharmaceutical company reported ($1.70) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.75) by $0.05. The biopharmaceutical company had revenue of $4.90 million for the quarter, compared to analysts' expectations of $5.74 million. (KITE)'s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.54) EPS.
What other stocks do shareholders of (KITE) own?: Based on aggregate information from My MarketBeat watchlists, some companies that other (KITE) investors own include Puma Biotechnology (PBYI), (MDVN) (MDVN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Airlines (UAL), Juno Therapeutics (JUNO), Array Technologies (ARRY) and bluebird bio (BLUE).

What is (KITE)'s stock symbol?: (KITE) trades on the NASDAQ under the ticker symbol "KITE."
What is (KITE)'s stock price today?: One share of KITE stock can currently be purchased for approximately $179.79.
How can I contact (KITE)?: (KITE)'s mailing address is 2225 Colorado Ave, SANTA MONICA, CA 90404-3505, United States. The official website for the company is www.kitepharma.com. The biopharmaceutical company can be reached via phone at +1-310-8249999.

This page (NASDAQ:KITE) was last updated on 3/25/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

(KITE) - KITE Stock Forecast, Price & News

About (KITE) (NASDAQ:KITE) Stock

KITE Stock News Headlines

KITE Company Calendar

Industry, Sector and Symbol

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

KITE Stock - Frequently Asked Questions

About MarketBeat

Popular Tools

Financial Calendars

Terms & Info